317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

John Wilkerson, a Washington Correspondent for STAT, dives into the intense landscape of drug pricing negotiations under the Inflation Reduction Act. He sheds light on the implications these negotiations have for the biotech sector. The discussion also highlights the merger between AI drug firms Recursion Pharmaceuticals and Exscientia. Additionally, Wilkerson touches on Novo Nordisk's pause on Wegovy's regulatory submission for heart failure patients, revealing the complex dynamics of pharmaceutical acquisitions in a competitive market.